Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,57,79149.8% delivered
Sun Pharmaceutical Industries share news and announcements
1,454 announcements, routine notices left out, newest first. Page 24 of 30.
May 2012
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2012 has recommended payment of dividend of Rs.4.25 per equity share of Re.1 each for the year ended March 31, 2012 subject to approval of members at ensuing Annual General Meeting.29 May · Results
Consolidated Results for the year ended on 31-MAR-2012 as follows: Net Sales of Rs. 800566 lacs for year ending on 31-MAR-2012 against Rs. 572143 lacs for the year ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 258725 lacs for the year ending on 31-MAR-2012 against Rs. 181606 lacs for the year ending on 31-MAR-2011.15 May · Board meeting
Interalia, (1) To consider and approve the audited financial results of the Company for the year ended March 31, 2012; (2) To consider the recommendation of payment of dividend on equity shares for the year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Apr 2012
2 Apr · Management
On account of increasing strategic importance of the Group's business interests in North and South America, Mr. Kalyanasundaram Subramanian, now directly responsible for these businesses, shall soon relocate to the USA. Hence, he has resigned as the Director of the Company with effect from March 31, 2012.
Mar 2012
Feb 2012
13 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 63121 lacs for quarter ending on 31-DEC-2011 against Rs. 56478 lacs for the quarter ending on 30-SEP-2011. Net Profit / (Loss) of Rs. 36523 lacs for the quarter ending on 31-DEC-2011 against Rs. 43755 lacs for the quarter ending on 30-SEP-2011.13 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 214513 lacs for quarter ending on 31-DEC-2011 against Rs. 160107 lacs for the quarter ending on 31-DEC-2010. Net Profit / (Loss) of Rs. 66830 lacs for the quarter ending on 31-DEC-2011 against Rs. 35015 lacs for the quarter ending on 31-DEC-2010.2 Feb · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter/ nine months ended December 31, 2011.
Jan 2012
Dec 2011
Nov 2011
3 Nov · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2011.
Oct 2011
18 Oct · Updates
On October 18, 2011, the Company (together with its subsidiaries & affiliates, "Sun Pharma") delivered a letter to Sun Pharma's Israeli subsidiary, Taro Pharmaceutical Industries Ltd's Board of Directors proposing acquisition by Sun Pharma, of all of the outstanding shares of Taro not held by Sun Pharma for per share consideration of US $ 24.50 in cash representing a 25.96% premium over the most recent closing price of Taro common stock. This offer is subject to the approval of Taro Board and such other authorities as may be required and subject to completion of necessary cornpllances/formalities as may be required.
Sep 2011
Aug 2011
12 Aug · Meeting
Register of Members and Share Transfer Books of the Company will be closed from September 06, 2011 to September 16, 2011 (both days inclusive) for the purpose of payment of dividend for the year ended March 31, 2011 and for the purpose of Annual General Meeting of the Company to be held on September 16, 2011.
Jul 2011
28 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 163572 lacs for quarter ending on 30-JUN-2011 against Rs. 139970 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 50100 lacs for the quarter ending on 30-JUN-2011 against Rs. 56432 lacs for the quarter ending on 30-JUN-2010.28 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 52119 lacs for quarter ending on 30-JUN-2011 against Rs. 49888 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 42320 lacs for the quarter ending on 30-JUN-2011 against Rs. 32263 lacs for the quarter ending on 30-JUN-2010.20 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 2011.
Jun 2011
1 Jun · Dividend
Board of Directors of the Company at its meeting held on May 28, 2011 has recommended payment of dividend of Rs.3.50 per equity share of Rs.1 each for the year ended March 31, 2011 subject to approval of members at ensuing Annual General Meeting.